Epetraborole

DRUG5 trials

Sponsors

AN2 Therapeutics, Inc, Kevin Winthrop

Conditions

Healthy VolunteersMAC Lung DiseaseMycobacterium Abscessus InfectionRenal InsufficiencyTreatment Refractory MAC Lung Disease

Phase 1

Phase 1 Study of Epetraborole Tablets

CompletedNCT04892641

AN2 Therapeutics, IncHealthy Volunteers

Start: 2021-06-10End: 2022-02-26Updated: 2024-03-21

A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function

CompletedNCT05283746

AN2 Therapeutics, IncRenal Insufficiency

Start: 2022-02-21End: 2022-06-27Updated: 2022-07-15

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

CompletedNCT05995444

AN2 Therapeutics, IncHealthy Volunteers

Start: 2023-06-05End: 2023-08-03Updated: 2023-12-21

Phase 2

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

TerminatedNCT05327803

AN2 Therapeutics, IncMAC Lung Disease, Treatment Refractory MAC Lung Disease

Start: 2022-05-20End: 2024-12-18Updated: 2026-06-10

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

RecruitingNCT07301320

Kevin WinthropMycobacterium Abscessus Infection

Start: 2026-03-30End: 2028-05-01Target: 84Updated: 2026-05-06

Related Papers

Recombinant interleukin-7 treatment of refractory <i>Mycobacterium avium</i> complex lung disease (IMPULSE-7): a pilot phase II, single-center, randomized, clinical trial

Therapeutic Advances in Infectious Disease2025-05-101 citations

593. Population Pharmacokinetic Model Development for Epetraborole and <i>Mycobacterium avium</i> Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies

Open Forum Infectious Diseases2022-12-012 citations